Cost of the Personal

While genome sequencing may enable more personalized medicine, an article in Vancouver Sun examines how it may also lead to more expensive drugs. Because therapeutics targeted against certain genetic mutations may only then be effective in a sliver of the population, Randy Shore writes in the Sun that such 'orphan drugs' could command prices ranging between $100,000 and $1 million a year for each patient.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.